We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
+43.96%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$700M
AUM Growth
-$785M
Cap. Flow
-$1.24B
Cap. Flow %
-177.44%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
3 quarters
Top 10 Avg Time Held
3 quarters
Top 20 Avg Time Held
3 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.24B

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$29.9B
$635M 90.64%
1,392,303
-3,052,142
-69% -$1.24B
2024 Q4
3 quarters
NTLA icon
2
Intellia Therapeutics
NTLA
$1.67B
$64M 9.13%
3,702,995
– –
2024 Q4
3 quarters
ADVM icon
3
DELISTED
Adverum Biotechnologies
ADVM
$820K 0.12%
180,909
– –
2024 Q4
3 quarters
ACET icon
4
Adicet Bio
ACET
$47.8M
$784K 0.11%
60,511
– –
2024 Q4
3 quarters

Similar funds

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
WFG
Wormser Freres Gestion Paris, France $177M AUM 13.84% 1-Year Est. Return
AAS
AdviceOne Advisory Services Glastonbury, Connecticut $177M AUM 26.65% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Regeneron Pharmaceuticals's Q3 2025 Portfolio in Review

As of Q3 2025, Regeneron Pharmaceuticals held 4 positions worth $700M, down 53% from $1.49B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Regeneron Pharmaceuticals withdrew a net $1.24B in Q3 2025, reducing 1 holding. Its largest reduction was Alnylam Pharmaceuticals, cutting an estimated $1.24B.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Regeneron Pharmaceuticals's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $1.24B.
  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $700M portfolio in Q3 2025.
  • Regeneron Pharmaceuticals opened 0 new positions and closed 0 in Q3 2025.
  • Regeneron Pharmaceuticals's portfolio value fell 53% quarter-over-quarter to $700M.

Based on Regeneron Pharmaceuticals's 13F filing for Q3 2025, filed 7 Nov 2025.